Development of Natural and Synthetic Antivirus Materials Using Artificial Intelligence Technology
1. R&D Objective
BOSON Bioscience is exploring and excavating synthetic and natural materials using artificial intelligence technology to develop treatments for viral diseases. In addition, if prior research proves safe and effective treatment options, a rapid regulatory process is used to design a wide range of options for clinical verification. In addition, we are building a broad portfolio of antiviral drugs and focusing our efforts on research that can respond to unpredictable viruses.
2. R&D Performances
The researchers of BOSON Bioscience began research on the development of treatments for African Swine Fever Virus (ASFV) and Rhinovirus in 2010 and are conducting efficacy and safety tests on candidate substances (BS-C19) that are effective for COVID-19 in 2020.
In addition, we conducted a joint study on herpes and coronavirus with researchers from Korea University and Chungbuk National University's College of Pharmacy. Based on this, we are planning to apply for a pre-qualification examination in 2020 and obtain certification in 2021. BOSON Bioscience will strive for a healthier life for humanity through its ability to develop world-class treatments.
Manufacture technology for Candida Bombicola Forment
Medicine application for BS-H20, Herpes
AI+Bio Convergence Technology
Exploring and Testing Natural Materials Using AI Technology
BS-C19, COVID-19 Antivirus Treatment Development Application
BS-V20, development and application of flu antiviral drugs